Related Experiment Video
Updated: Jul 14, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Advances in lipid-lowering therapy in atherosclerosis
1Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, Quebec.
Advances in Experimental Medicine and Biology
|March 20, 2002
Summary
Lipid-lowering therapies like statins and fibrates effectively reduce cardiovascular events by lowering LDL-C and triglycerides. Combining these drugs may offer greater benefits, with ongoing trials investigating their synergistic effects.
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Diseases
Background:
- Lipid-lowering therapy is crucial for managing atherosclerosis and coronary artery disease (CAD).
- While LDL-C reduction is primary, HDL-C elevation and triglyceride-rich lipoprotein (TRL) reduction are also important.
- Treatment strategies must consider dyslipidemia type, drug interactions, and pleiotropic effects.
Purpose of the Study:
- To review the roles of statins and fibrates in lipid management and cardiovascular disease prevention.
- To highlight the complementary lipid-modifying and pleiotropic effects of statins and fibrates.
- To discuss the rationale for combination therapy and its ongoing investigation.
Main Methods:
- Review of current evidence on statins and fibrates.
- Discussion of mechanisms of action, including PPAR alpha pathway for fibrates.
- Mention of the Lipid in Diabetes Study (LDS) as a key ongoing trial.
Main Results:
- Fibrates significantly reduce TRL and increase HDL-C, with PPAR alpha mediation.
- Statins are potent LDL-C reducers with numerous pleiotropic benefits (anti-inflammatory, anti-thrombotic, etc.).
- Combined therapy of statins and fibrates shows promise for enhanced cardiovascular benefit.
Conclusions:
- Statins and fibrates possess complementary lipid-modifying and pleiotropic effects.
- Combination therapy, used cautiously, is hypothesized to provide maximal cardiovascular protection.
- Further research, like the LDS trial, is essential to confirm the benefits of combined lipid-lowering strategies.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:23Atherosclerosis IV: Nursing Management
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...